Mammary Cell News 8.48 December 8, 2016 | |
| |
TOP STORYResearchers found that treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improved outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer. [JAMA] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHThe authors showed that the SCN4B gene, encoding for the β4 protein, initially characterized as an auxiliary subunit of voltage-gated sodium channels in excitable tissues, was expressed in normal epithelial cells and that reduced β4 protein levels in breast cancer biopsies correlate with high-grade primary and metastatic tumors. [Nat Commun] Full Article A TGFβ–miR-182–BRCA1 Axis Controls the Mammary Differentiation Hierarchy Scientists showed that transforming growth factor–β (TGFβ) exerts control of mammary progenitor self-renewal and lineage commitment decisions by stringent regulation of breast cancer associated 1, which controls stem cell self-renewal and lineage commitment. [Sci Signal] Abstract The authors demonstrated that inhibition of the SUMO pathway repressed MMP14 and CD44 with a concomitant reduction in cell invasiveness and functional loss of cancer stem cells in basal breast cancer. Identical results were obtained in a colorectal cancer cell line and primary colon cancer cells. [Stem Cell Reports] Full Article ‘Normalizing’ the Malignant Phenotype of Luminal Breast Cancer Cells via Alpha(v)Beta(3)-Integrin Scientists demonstrated that alpha(v)beta(3) integrin, previously shown to play a role in cancer progression, promoted differentiation and growth arrest of organoids derived from luminal A breast cancer cells grown in their relevant three-dimensional microenvironment. These organoids differentiated into normal-like acini resembling a benign stage of breast tissue. [Cell Death Dis] Full Article Bcl-3 Regulates TGFβ Signaling by Stabilizing Smad3 during Breast Cancer Pulmonary Metastasis Investigators showed that Bcl-3, a member of the IκB family, serves as a critical regulator in transforming growth factor–β (TGFβ) signaling to modulate breast cancer pulmonary metastasis. Bcl-3 expression was significantly associated with metastasis-free survival in breast cancer patients. [Cell Death Dis] Full Article The authors, based on co-crystallization studies and pharmacophore-docking-based virtual screening, discovered a series of dihydrodibenzo[b,e]-oxepin compounds as poly (ADP-ribose) polymerase-1 (PARP1) inhibitors. PARP1 is a highly conserved enzyme focused on the self-repair of cellular DNA damage. [Sci Rep] Full Article Scientists investigated the effects of silencing the HAS-2 gene on the proliferation and apoptosis of human breast cancer cells. The HAS-2-siRNA group showed decreased expression of HAS-2 relative to that in the control and scrambled siRNA groups. [Cell Physiol Biochem] Full Article Researchers investigated the potential role of exosomes in the process of psoralen reverse multidrug resistance of MCF-7/ADR cells. They showed that exosomes derived from MCF-7/ADR cells were able to promote active sequestration of drugs and could induce a drug resistance phenotype by transferring drug-resistance-related gene MDR-1 and P-glycoprotein protein. Psoralen could reduce the formation and secretion of exosomes to overcome drug resistance. [J Exp Clin Cancer Res] Full Article Scientists explored the efficacy of bone marrow as alternative in vivo source of natural killer (NK) cells for anti-breast cancer treatment. Administration of 2.5 alloreactive NK cells significantly reduced progression-free survival. [Breast Cancer Res Treat] Full Article Adenosine Stimulate Proliferation and Migration in Triple Negative Breast Cancer Cells Investigators showed that adenosine increases proliferation and migration in a triple negative breast cancer model, the MDA-MB 231 cell line. The use of specific agonists and antagonists evidenced that these effects depend on the activation of the A2B receptor, which then triggers an intracellular response mediated by the adenylate cyclase/PKA/cAMP signaling pathway. [PLoS One] Full Article Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells Accumulating evidences suggest Aryl hydrocarbon receptor (Ahr), a helix-loop-helix transcription factor, as a promising target to control migration and invasion in breast cancer cells. The authors found that the in silico and in vitro results identified Flavipin as a novel Ahr agonist. [PLoS One] Full Article | |
| |
REVIEWSFrom Transformation to Metastasis: Deconstructing the Extracellular Matrix in Breast Cancer The authors address the contribution of extracellular matrix (ECM) mechanics to breast cancer progression, metastasis, and treatment resistance and discuss potential therapeutic strategies targeting the ECM. [Cancer Metastasis Rev] Abstract The Role of HER2, EGFR, and Other Receptor Tyrosine Kinases in Breast Cancer The authors provide a brief summary on the role of a selected number of receptor tyrosine kinases in breast cancer and describe some mechanisms of resistance to targeted therapies. [Cancer Metastasis Rev] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSPuma Biotechnology, Inc. announced updated interim results from an ongoing Phase II clinical trial of Puma’s investigational drug PB272, given as monotherapy and in combination with the anticancer drug fulvestrant. [Press release from Puma Biotechnology, Inc. discussing research presented at the 2016 San Antonio Breast Cancer Symposium, San Antonio] Press Release | |
| |
INDUSTRY NEWSAmerican Cancer Society Approves New Research and Training Grants at Yale University The American Cancer Society has approved funding for three new research grants totaling over $1.7 million to investigators at Yale University. These grants are among 11 new projects in effect across New England as of January 1, 2017 totaling more than $4.4 million dollars. [Yale School of Medicine] Press Release AbbVie and Johns Hopkins to Collaborate on Cancer Research AbbVie and the Johns Hopkins University School of Medicine announced that they signed a five-year collaboration agreement with the goal of advancing medical oncology research and discovery at both organizations. Designed to build strong collaboration between AbbVie and Johns Hopkins Medicine researchers, the agreement will focus on several areas of oncology research, which could include lung, colorectal, breast, prostate and hematological cancer. [AbbVie Inc.] Press Release The Breast Cancer Research Foundation (BCRF) announced nine new projects that are part of a collaboration between BCRF, Pfizer and the Translational Breast Cancer Research Consortium. The program — funded with an initial $15 million commitment from Pfizer along with newly available access to Pfizer’s broad portfolio of approved products and its pipeline of oncology drugs still under development — will support six laboratory studies and three clinical trials. [Breast Cancer Research Foundation] Press Release | |
| |
POLICY NEWSSenate Sends Massive Biomedical Innovation Bill to Obama for Signing By a 94-to-five vote, the Senate approved the 21st Century Cures Act, clearing the way for President Barack Obama to sign the measure into law. The massive bill dedicates $4.8 billion over the next decade to research initiatives at the National Institutes of Health and makes an array of changes at the Food and Drug Administration designed to speed the approval of new drugs and medical devices. [ScienceInsider] Editorial Controversial Impact Factor Gets a Heavyweight Rival One of science’s most contentious metrics has a flashy new rival. Publishing giant Elsevier launched the CiteScore index to assess the quality of academic journals. Although the index ranks journals with a formula that largely mimics the influential Journal Impact Factor (JIF), it covers twice as many journals and its formula includes tweaks that produce some notably different results, including lower scores for some high-JIF journals. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia on Molecular and Cellular Biology NEW Stem Cells in Drug Discovery Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Researcher – Nuclear Medicine Dosimetry (University of Oxford) Postdoctoral Fellow – Breast Cancer Biology (Icahn School of Medicine at Mount Sinai) Postdoctoral Position – Breast and Lung Cancer (Cold Spring Harbor Laboratory) Postdoctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami) Assistant Professor – Molecular Therapeutics of Cancer (Dartmouth College) Research Fellow – Breast Cancer Research (Dana-Farber Cancer Institute) Postdoctoral Fellow – Cancer Prevention Studies (American Cancer Society) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|